Application of hyaluronic acid in improving the properties of polysaccharide-polypeptide composite hydrogel

By adding hyaluronic acid to the polysaccharide-polypeptide complex hydrogel, its structure and performance are optimized, and the stability and release control problems of the polypeptide complex hydrogel in drug delivery are solved, achieving high-efficiency loading of hydrophobic drugs and Delayed release, suitable for biomedical fields.

CN118557738BActive Publication Date: 2024-12-03上海瑞致生物科技有限公司
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411000525.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-12-03
Estimated Expiration
2044-07-25

AI Technical Summary

Technical Problem

In drug delivery, polypeptide composite hydrogels have problems such as unstable hydrogel properties, poor drug load capacity and inability to sustained and stable release of drug components, especially the difficulty in controlling the release rate of hydrophobic drugs.

Method used

By adding different concentrations of hyaluronic acid (HA) to the polysaccharide-polypeptide complex hydrogel, its effect on rheological properties, degradation rate, drug load capacity and release rate, the preparation method of HA/Fmoc-FRGDF is used. Combined with technical means such as Fourier infrared spectroscopy, circular dichromatograph and transmission electron microscopy, the structure and performance of hydrogels are optimized.

Benefits of technology

HA can reduce the mechanical properties of polysaccharide-polypeptide composite hydrogels, delay their degradation rate, improve the load capacity of hydrophobic drugs and delay their release rate, improve the stability and biocompatibility of hydrogels, and is suitable for mechanical strength. Low extracellular matrix and drug delivery applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118557738B_ABST
    Figure CN118557738B_ABST
Patent Text Reader

Abstract

The present invention belongs to the technical field of novel biomaterials, and discloses the application of hyaluronic acid in improving the performance of polysaccharide-polypeptide composite hydrogels. Based on the self-assembly characteristics of polypeptides, the present invention prepares polysaccharide-polypeptide composite hydrogels with different concentrations of hyaluronic acid (HA). It has been verified that compared with single polypeptide hydrogels without HA, HA reduces the mechanical properties of the composite gel, but can still delay the degradation rate of the composite hydrogel and improve its stability. HA can also improve the loading capacity of the composite hydrogel for quercetin and dihydroflavonoid glycosides, and delay the in vitro release of the two, which is conducive to the sustained release of active substances. In addition, the addition of HA does not affect the secondary structure and micro-nanostructure of the composite hydrogel, and can also increase the strength of the non-covalent interaction force between molecules and improve the stability of the composite hydrogel. The present invention explores the influence of HA on the performance of the composite hydrogel, and provides a theoretical basis for the study of hydrophobic drug delivery carriers.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of novel biomaterials and relates to the application of hyaluronic acid in improving the performance of polysaccharide-polypeptide composite hydrogel. Background Art

[0002] The self-assembly of polypeptides refers to the formation of nanoscale fiber structures under specific conditions by various non-covalent binding forces between molecules. Self-assembling polypeptide hydrogels are semi-solid transparent gels produced by the self-assembly of polypeptides using polypeptide molecules as gel factors. Self-assembling polypeptide hydrogels have good application prospects in the biomedical field, such as drug delivery, tissue engineering, etc.

[0003] Polysaccharide-polypeptide composite hydrogel is a composite hydrogel with polysaccharide and polypeptide as core functional components. As a new type of biomaterial, it has the advantages of good biocompatibility, good hydrophilicity, and degradability. It has good application potential in the fields of drug or active biomacromolecule delivery, tissue repair, artificial organs, etc. Among them, hyaluronic acid (HA), as a natural mucopolysaccharide, is the main component of the natural cell matrix and is widely present in related tissues such as the skin, vitreous humor and synovial fluid of the eyes. HA has the advantages of excellent biocompatibility, water absorption, high viscoelasticity, non-antigenic action and non-toxicity to the degradation process, and is widely used in food, medicine, health care products and other fields.

[0004] At present, there are still many problems in the application of polypeptide composite hydrogels. For example, when polypeptide composite hydrogels are used as drug delivery carriers, there are problems such as unstable hydrogel properties, poor drug loading capacity, low drug encapsulation rate, and inability to continuously and stably release drug components. Therefore, how to improve the stability of polypeptide composite hydrogels, improve their drug loading capacity, and delay the release rate of drugs, especially hydrophobic drug components, is an urgent problem to be solved. Summary of the invention

[0005] In order to solve the problems of unstable hydrogel properties, poor drug loading capacity and inability to continuously and stably release drug components when polypeptide hydrogel is used as a drug delivery carrier, the present invention provides the use of hyaluronic acid in improving the performance of polypeptide hydrogel.

[0006] The present invention prepares polypeptide composite hydrogels (i.e., HA / Fmoc-FRGDF) with different concentrations of polysaccharides to study the effects of different concentrations of HA on the structure and properties of HA / Fmoc-FRGDF. First, through the changes in storage modulus (G') and energy loss modulus (G"), how HA affects the rheological properties of HA / Fmoc-FRGDF is analyzed, and then the effect of HA on the secondary structure of HA / Fmoc-FRGDF is determined by Fourier transform infrared spectroscopy (FTIR) and circular dichroism spectrometer (CD), and then the internal structure of the gel is observed by transmission electron microscopy (TEM). Secondly, an in vitro degradation test is performed on HA / Fmoc-FRGDF to clarify the effect of HA on the in vitro degradation rate of HA / Fmoc-FRGDF. Finally, quercetin (Que) and dihydroflavonoid glycoside (Hes) are used as hydrophobic drug models to test the loading capacity and controlled release effect of HA / Fmoc-FRGDF on Que and Hes. Based on the above technical ideas, the present invention provides the following technical solutions.

[0007] The present invention provides the application of hyaluronic acid in improving the performance of polysaccharide-polypeptide composite hydrogel, specifically including: HA is used to reduce the mechanical properties of polysaccharide-polypeptide composite hydrogel, or to delay the degradation rate of polysaccharide-polypeptide composite hydrogel, or to enhance the loading capacity of polysaccharide-polypeptide composite hydrogel for hydrophobic drugs, or to delay the release rate of hydrophobic drugs in polysaccharide-polypeptide composite hydrogel.

[0008] Furthermore, in the application, within the concentration range of 0.1-1.5 mg / mL, HA can reduce the storage modulus (G') and loss modulus (G") of the polysaccharide-polypeptide composite hydrogel.

[0009] Furthermore, in the application, within the concentration range of 0.1 to 1.5 mg / mL, HA can slow down the degradation rate of the polysaccharide-polypeptide composite hydrogel.

[0010] Furthermore, in the application, within the concentration range of 0.1 to 1.5 mg / mL, HA can enhance the loading capacity of the polysaccharide-polypeptide composite hydrogel for hydrophobic drugs.

[0011] Furthermore, in the application, within the concentration range of 0.1 to 1.5 mg / mL, HA can delay the release rate of hydrophobic drugs in the polysaccharide-polypeptide composite hydrogel.

[0012] Furthermore, in the application, the polypeptide is Fmoc-FRGDF, and the hydrophobic drug is a hydrophobic substance soluble in alkaline solution, such as quercetin or dihydroflavonoid glycoside.

[0013] Furthermore, in the application, the preparation method of the polysaccharide-polypeptide composite hydrogel includes: dissolving hyaluronic acid and polypeptide in water, adding NaOH solution, HCl solution, and PBS buffer, shaking to dissolve and defoam.

[0014] Furthermore, in the application, the ratio of the raw materials is: 70 μL NaOH solution, 65 μL HCl solution, 465 μL PBS buffer and 10 mg polypeptide are used in every 400 μL water.

[0015] Furthermore, in the application, the concentration of NaOH solution is 0.5M, the concentration of HCl solution is 0.1M, the concentration of PBS buffer is 0.1M, and pH=7.4.

[0016] Furthermore, in the application, the content of hyaluronic acid in the polysaccharide-polypeptide composite hydrogel is ≥ 0.1 mg / mL.

[0017] Compared with the prior art, the application of hyaluronic acid in improving the performance of polysaccharide-polypeptide composite hydrogel has the following beneficial effects:

[0018] HA has the effect of reducing its mechanical properties under the premise of delaying the degradation rate of HA / Fmoc-FRGDF. The design and construction of hydrogels with tissue-specific mechanical properties play an important role in the stability of the cell microenvironment and the performance of biological functions. Compared with polysaccharide-peptide composite hydrogels with high mechanical strength, composite hydrogels with lower mechanical properties are beneficial for application in parts with lower mechanical strength of the extracellular matrix, such as the brain and other parts. The elasticity of different parts of the human body is very different, such as the elastic modulus of the brain is 100~1000Pa, the elastic modulus of striated muscle is 8000~17000Pa, and the elastic modulus of cross-linked collagen is 25000~40000Pa. Polysaccharide-peptide composite hydrogels with low mechanical strength have better biocompatibility and higher plasticity, and are more easily processed into various shapes and sizes to meet different application requirements. The HA / Fmoc-FRGDF hydrogel provided by the present invention reduces its mechanical properties under the premise of delaying the degradation rate of HA / Fmoc-FRGDF, and can be used for extracellular matrices with lower mechanical strength.

[0019] HA can slow down the degradation rate of HA / Fmoc-FRGDF. The results of in vitro degradation test of HA / Fmoc-FRGDF showed that: with the extension of time, the residual mass percentage of A0 decreased the fastest, and only 4.34% remained at 192h, indicating that its degradation rate was the fastest. A2 had 10.46% remaining at 192h, indicating that the addition of HA can slow down the degradation rate of HA / Fmoc-FRGDF and improve the stability of hydrogel, which is of great significance for the sustained release of active substances.

[0020] HA can improve the loading capacity of HA / Fmoc-FRGDF for quercetin (Que) and dihydroflavonoids (Hes). The encapsulation efficiency of HA / Fmoc-FRGDF hydrogel loaded with Que increased with the increase of concentration, reaching a maximum of 90.29%, which is 17.00% higher than the polypeptide hydrogel without HA (i.e. A0). The encapsulation efficiency of HA / Fmoc-FRGDF hydrogel loaded with Hes increased with the increase of concentration, reaching a maximum of 97.60%, which is 50.79% higher than the polypeptide hydrogel without HA (i.e. A0). This shows that HA in HA / Fmoc-FRGDF can improve its loading capacity for Que and Hes and accommodate more Que and Hes.

[0021] HA can slow down the release rate of Que in HA / Fmoc-FRGDF. In the polypeptide hydrogel without HA (i.e. A0), the release rate of Que was the fastest, followed by A2, A1, A4 and A3 with HA, indicating that HA can significantly reduce the release rate of Que and alleviate the problem of hydrophobic drugs not being able to be released continuously and stably in composite hydrogels.

[0022] In addition, through Fourier infrared spectroscopy (FTIR) and circular dichroism (CD) analysis, the secondary structure of HA / Fmoc-FRGDF is a β-fold arrangement, and the addition of HA will not affect the secondary structure of HA / Fmoc-FRGDF. Moreover, the addition of HA also promotes the strength of intermolecular interactions and the stability of HA / Fmoc-FRGDF. The higher the HA concentration, the stronger the absorption peak. In addition, in the circular dichroism spectrum, the 230~270nm region shows that the polypeptide nanofibers form a supramolecular arrangement. The addition of Que greatly enhances the peak intensity in the 230~270nm region, indicating that Que enhances the supramolecular structure order.

[0023] Transmission electron microscopy (TEM) results showed that the hydrogels with added HA formed nanofibers, HA did not change the micro-nanostructure of the polysaccharide-polypeptide composite hydrogel, and the nanostructure of the composite hydrogel loaded with Que was also not changed. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 It is the change of storage modulus (G') of HA / Fmoc-FRGDF under different HA concentration conditions.

[0025] Figure 2 The figure shows the change of energy loss modulus (G") of HA / Fmoc-FRGDF under different HA concentration conditions.

[0026] Figure 3This is the Fourier transform infrared spectrum (FTIR) of HA / Fmoc-FRGDF.

[0027] Figure 4 HA / Fmoc-FRGDF at 1550~1750cm -1 Zoomed-in FTIR image over the frequency range.

[0028] Figure 5 Circular dichroism (CD) analysis diagrams of single Fmoc-FRGDF hydrogel, HA / Fmoc-FRGDF (A1~A4) and Que-loaded HA / Fmoc-FRGDF hydrogel (B2) in the wavelength range of 190~300nm.

[0029] Figure 6 The remaining mass percentage of HA / Fmoc-FRGDF in PBS buffer changes with time.

[0030] Figure 7 The release amount of HA / Fmoc-FRGDF hydrogel loaded with Que changes at different times.

[0031] Figure 8 Transmission electron microscopy (TEM) image of Que-loaded HA / Fmoc-FRGDF hydrogel.

[0032] Explanation of the figure marks: A0 represents a single Fmoc-FRGDF hydrogel without added HA; A1 represents HA / Fmoc-FRGDF with a HA concentration of 0.1 mg / mL; A2 represents HA / Fmoc-FRGDF with a HA concentration of 0.5 mg / mL; A3 represents HA / Fmoc-FRGDF with a HA concentration of 1.0 mg / mL; A4 represents HA / Fmoc-FRGDF with a HA concentration of 1.5 mg / mL. DETAILED DESCRIPTION

[0033] The technical scheme of the present invention is described clearly and completely below in conjunction with the embodiments. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0034] The molecular weight of the hyaluronic acid used in the embodiment is 40-100 kDa, and the purity is 97%; the polypeptide is Fmoc-FRGDF, and the purity is>95%; the purity of the quercetin and dihydroflavonoids used is 95%; the concentration of the potassium phosphate buffer (PBS) used is 0.1 M, and the pH is 7.4.

[0035] Example 1

[0036] This example provides the preparation of polysaccharide-polypeptide composite hydrogel (ie, HA / Fmoc-FRGDF).

[0037] Accurately weigh 0, 0.1, 0.5, 1.0, and 1.5 mg of hyaluronic acid into small glass bottles, and number them accordingly: A0 (HA, 0 mg / mL), A1 (HA, 0.1 mg / mL), A2 (HA, 0.5 mg / mL), A3 (HA, 1.0 mg / mL), and A4 (HA, 1.5 mg / mL).

[0038] Add the following to each small glass bottle: 10 mg of polypeptide (Fmoc-FRGDF), 400 μL of ultrapure water, 70 μL of 0.5 M NaOH solution, 65 μL of 0.1 M HCl solution, and 465 μL of PBS buffer solution. All the reagents listed were added while shaking.

[0039] The mixture was shaken by a vortex oscillator until HA and Fmoc-FRGDF were completely dissolved. After ultrasonic defoaming, the mixture was allowed to stand at room temperature for 24 hours to obtain HA / Fmoc-FRGDF.

[0040] Example 2

[0041] This example provides the determination of rheological properties of HA / Fmoc-FRGDF.

[0042] HA / Fmoc-FRGDF was prepared by the method in Example 1. The prepared HA / Fmoc-FRGDF samples (A0-A4) were measured for storage modulus (G') and loss modulus (G") in the linear viscoelastic range using a HAAKE MARS modular advanced rheometer under the following conditions: shear stress of 1%, frequency of 0.1-100 Hz, and temperature of 25°C.

[0043] Figure 1 It is the change of storage modulus (G') of HA / Fmoc-FRGDF under different HA concentration conditions. Figure 2 is the change of HA / Fmoc-FRGDF energy loss modulus (G") under different HA concentration conditions. Figure 1~2It can be seen that HA / Fmoc-FRGDF prepared with different HA concentrations all show viscoelastic gel behavior, and in the frequency range shown in the figure, the storage modulus (G') is higher than the loss modulus (G"). The storage modulus (G') of the single Fmoc-FRGDF hydrogel (A0) is the highest, and the storage modulus (G') of the composite hydrogel after adding HA is lower than that of the single Fmoc-FRGDF hydrogel at different frequencies, indicating that HA reduces the mechanical properties of the hydrogel. This change in the storage modulus (G') is due to the good water absorption of hyaluronic acid, which leads to an increase in the water content of the gel and a decrease in elasticity.

[0044] Example 3

[0045] This example provides secondary structure analysis of HA / Fmoc-FRGDF.

[0046] 1. After freeze-drying, a small amount of HA / Fmoc-FRGDF sample was mixed with dried potassium bromide, ground and pressed into tablets. Pure potassium bromide tablets were used as blank controls and analyzed using Tensor27 Fourier transform infrared spectrometer (FTIR). The analysis conditions were: wave number range 400~4000cm -1 , resolution 4cm -1 , the number of scans is 32 times.

[0047] Figure 3 This is the FTIR spectrum of HA / Fmoc-FRGDF. Fmoc-FRGDF is at 3294 cm -1 The NH and OH stretching vibration peaks of the amide A band are at 1636 cm -1 and 1690cm -1 There is a characteristic absorption peak of β-folding at 1079cm -1 The peak at is C-HC-N (amine) stretching peak.

[0048] Figure 4 HA / Fmoc-FRGDF at 1550~1750cm -1 FTIR zoomed in on the frequency range. Figure 4 It can be seen that the characteristic absorption peaks of Fmoc-FRGDF and HA / Fmoc-FRGDF of different concentrations are similar, both at 1636 cm -1 The β-folding absorption peak appears at 1600~1700cm -1Vibrations within this range are usually used to determine the secondary structure of the peptide chain. It is known that no new chemical bonds are generated in HA / Fmoc-FRGDF, indicating that the addition of HA does not affect the secondary structure of the peptide in the gel. In addition, the addition of HA also promotes the strength of the interaction between molecules and the stability of HA / Fmoc-FRGDF. The higher the HA concentration, the stronger the absorption peak.

[0049] 2. The HA / Fmoc-FRGDF sample was diluted to 0.01wt%, and the sample spectrum was recorded using a circular dichroism spectrometer with a wavelength of 190-300nm and a resolution of 1nm at room temperature. All tests were repeated 3 times and the average value was taken.

[0050] Figure 5 The circular dichroism (CD) analysis diagram of single Fmoc-FRGDF hydrogel, HA / Fmoc-FRGDF (A1~A4) and HA / Fmoc-FRGDF hydrogel loaded with Que (B2) in the wavelength range of 190~300nm. Figure 5 It can be seen that the negative peak in the 190-220nm region indicates the presence of β-folding, while the 230-270nm region indicates that the polypeptide nanofibers form a supramolecular arrangement structure and form a gel macroscopically. The addition of Que greatly enhances the peak intensity in the 230-270nm region, indicating that the addition of Que enhances the strength of the supramolecular arrangement structure.

[0051] Example 4

[0052] This example provides an in vitro degradation test of HA / Fmoc-FRGDF.

[0053] According to the method in Example 1, HA / Fmoc-FRGDF samples with concentrations of A0, A1, A2, A3, and A4 were prepared. Take 1 mL of HA / Fmoc-FRGDF sample, add 2 mL of PBS buffer respectively, keep it in a closed container, place it in a 37°C, 100r / min shaking incubator, remove 2.0 mL of supernatant at 0, 24, 48, 72, 96, 120, 144, 168, and 192h, respectively, wipe with a paper towel for dehydration, and weigh the sample mass, and finally add an equal volume of fresh PBS buffer, with 3 replicates for each group. Record the weight loss of the sample during the whole process and draw a degradation curve. Calculation method for the residual weight ratio of the hydrogel:

[0054] The remaining weight ratio of hydrogel (%) = (W t / W 0 )×100%;

[0055] Where W t and W 0represents the remaining hydrogel weight at a set time point, W 0 The initial weight of the hydrogel is the average of 3 measurements.

[0056] Figure 6 is the change of the remaining mass percentage of HA / Fmoc-FRGDF in PBS buffer over time. Figure 6 It can be seen that with the extension of time, the remaining mass percentage of A0 decreased the fastest, and only 4.34% remained at 192h, indicating that its degradation rate was the fastest. A2 had 10.46% remaining at 192h, indicating that the addition of HA can delay the degradation rate of HA / Fmoc-FRGDF and improve the stability of the hydrogel, which is of great significance for the sustained release of active substances.

[0057] Example 5

[0058] This example provides a test of the loading capacity and controlled release capacity of HA / Fmoc-FRGDF for quercetin (Que).

[0059] 1. Encapsulation efficiency (EE) of Que in HA / Fmoc-FRGDF hydrogel loaded with Que

[0060] 30.76 mg of Que powder, 10 mg of Fmoc-FRGDF powder and 0, 0.1, 0.5, 1.0, and 1.5 mg of HA were weighed into centrifuge tubes and numbered A0 (HA, 0 mg / mL), A1 (HA, 0.1 mg / mL), A2 (HA, 0.5 mg / mL), A3 (HA, 1.0 mg / mL), and A4 (HA, 1.5 mg / mL).

[0061] To each centrifuge tube, add: 400 μL ultrapure water, 70 μL 0.5 M NaOH solution, 65 μL 0.1 M HCl solution, 465 μL PBS buffer solution. All the reagents listed are added while shaking.

[0062] The mixture was shaken by a vortex oscillator until HA and Fmoc-FRGDF were completely dissolved. After ultrasonic defoaming, the mixture was allowed to stand at room temperature for 24 h to obtain HA / Fmoc-FRGDF hydrogel loaded with Que.

[0063] The Que-loaded HA / Fmoc-FRGDF hydrogel was vortexed at 1500 r / min for 2 min, centrifuged at 10000 g for 10 min, and the supernatant was collected. The absorbance at 374 nm was measured using a spectrophotometer (TU-1901 double-beam UV-visible spectrophotometer). The concentration was calculated using the Que standard curve. Under the same conditions, Y = 1.2914X - 0.0032 (R 2=1.0000). The absorbance of samples of different concentrations was measured and the EE value of Que was calculated to characterize the loading capacity (results are shown in Table 1). EE calculation method:

[0064] EE (%) = (weight of Que in gel / total weight of Que) × 100%.

[0065] Table 1. EE values ​​of Que for HA / Fmoc-FRGDF hydrogel loaded with Que

[0066]

[0067] Note: The EE in Table 1 is the mean ± standard deviation (n=3).

[0068] Table 1 shows the statistical results of the EE value of Que in HA / Fmoc-FRGDF hydrogel loaded with Que. As shown in Table 1, with the increase of HA concentration, the EE value also increases, with the maximum value of 90.29%, which is 17% higher than the polypeptide hydrogel without HA (A0). This shows that in the HA / Fmoc-FRGDF hydrogel loaded with Que, HA can improve its loading capacity for Que and accommodate more Que.

[0069] 2. Test of controlled release ability of HA / Fmoc-FRGDF hydrogel loaded with Que

[0070] 1.0 mL of Que-loaded HA / Fmoc-FRGDF hydrogel was placed in a dialysis bag (100-500 Da), and then the dialysis bag was immersed in a beaker with 50 mL of PBS solution (the Que-loaded HA / Fmoc-FRGDF hydrogel contained the same concentration of HCl and NaOH solution), and the bag was sealed. The beaker was placed in a shaker at 37°C and 100 r / min, and 2 mL of PBS buffer in the beaker was taken at 0, 6, 12, 18, 24, 30, 36, 42, and 48 h, and the absorbance at 286 nm was measured (Y=1.2914X-0.0032; R 2 =1.0000; 2.5~100.0µg / mL), and add an equal amount of PBS buffer in the beaker.

[0071] Figure 7 The release amount of HA / Fmoc-FRGDF hydrogel loaded with Que changes at different times. Figure 7 It can be seen that the release rate of Que in the A0 group without HA was the fastest, followed by A2, A1, A4 and A3, indicating that HA has a significant delaying effect on the in vitro release of Que.

[0072] Example 6

[0073] This example provides the loading capacity of HA / Fmoc-FRGDF for dihydroflavonoid glycoside (Hes).

[0074] Weigh 2 mg of Hes powder, 10 mg of Fmoc-FRGDF powder and 0, 0.1, 0.5, 1.0, and 1.5 mg of HA into centrifuge tubes, and number them accordingly as A0 (HA, 0 mg / mL), A1 (HA, 0.1 mg / mL), A2 (HA, 0.5 mg / mL), A3 (HA, 1.0 mg / mL), and A4 (HA, 1.5 mg / mL).

[0075] To each centrifuge tube, add: 400 μL ultrapure water, 70 μL 0.5 M NaOH solution, 65 μL 0.1 M HCl solution, 465 μL PBS buffer solution. All the reagents listed are added while shaking.

[0076] The mixture was shaken by a vortex oscillator until HA and Fmoc-FRGDF were completely dissolved. After ultrasonic defoaming, the mixture was allowed to stand at room temperature for 24 hours to obtain HA / Fmoc-FRGDF hydrogel loaded with Hes.

[0077] The Hes-loaded HA / Fmoc-FRGDF hydrogel was vortexed at 1500 r / min for 2 min, centrifuged at 10000 g for 10 min, and the supernatant was collected. The absorbance at 286 nm was measured using a spectrophotometer. The concentration was calculated using the Hes standard curve. Under the same conditions, Y = 0.011X - 0.0242 (R 2 =0.9988). The absorbance of samples of different concentrations was measured and the EE value of Hes was calculated to characterize the loading capacity (results are shown in Table 2). EE calculation method:

[0078] EE (%) = (weight of Hes in gel / total weight of Hes) × 100%.

[0079] Table 2. EE values ​​of Hes loaded HA / Fmoc-FRGDF hydrogels for Hes

[0080]

[0081] Table 2 shows the statistical results of the EE value of Hes-loaded HA / Fmoc-FRGDF hydrogel for Que. As shown in Table 2, with the increase of HA concentration, the EE value also increases, with the maximum value of 97.60%, which is 50.79% higher than the polypeptide hydrogel (A0) without HA. This shows that in the Hes-loaded HA / Fmoc-FRGDF hydrogel, HA can improve its loading capacity for Hes and accommodate more Hes.

[0082] Example 7

[0083] This example provides TEM images of Que-loaded HA / Fmoc-FRGDF hydrogels.

[0084] HA / Fmoc-FRGDF samples with concentrations of A0, A1, A2, A3, and A4 were prepared according to the method in Example 1. HA / Fmoc-FRGDF hydrogel sample B2 loaded with Que (HA concentration of 0.5 mg / mL) was prepared according to the method in Example 5.

[0085] TEM images were obtained using a JEOL-2100 LaB6 transmission electron microscope (JEOL Ltd., Japan) with an operating voltage of 100 KV. A 300-mesh lace carbon film-coated copper grid was used as a sample holder. The hydrogel sample was diluted 5 times (20 µL hydrogel + 80 µL distilled water), and 12 µL of the diluted hydrogel sample was placed on the copper grid using a pipette, and allowed to adsorb for 30 seconds, and then excess liquid was removed using a separate Whatman filter paper (No. 1). One drop of negative NanoVan stain (Bio-Scientific Pty) was dropped on the parafilm M sealing film, and then the copper grid with the adsorbed hydrogel sample was placed on the NanoVan stain on the parafilm M sealing film, with the carbon side facing down, and stained for 5 minutes, then dried in the air with the carbon side facing up for 2 minutes, and finally placed in a copper grid box, dried overnight, and used for TEM imaging.

[0086] Figure 8 TEM image of HA / Fmoc-FRGDF hydrogel loaded with Que. Figure 8 It can be seen that all gel systems formed nanofibers, indicating that the addition of HA and Que did not destroy the nanofiber structure of the polypeptide.

[0087] In summary, the present invention prepares polysaccharide-polypeptide composite hydrogel HA / Fmoc-FRGDF with different concentrations to study the effect of different concentrations of HA on its structure and properties. The results show that HA has a direct effect on the network structure and drug release kinetics of HA / Fmoc-FRGDF.

[0088] First, HA reduces the storage modulus and energy loss modulus of HA / Fmoc-FRGDF. The HA / Fmoc-FRGDF hydrogel provided by the present invention reduces its mechanical properties while delaying the degradation rate of HA / Fmoc-FRGDF, and can be used for extracellular matrices with low mechanical strength. The secondary structure of HA / Fmoc-FRGDF is a β-folded arrangement, and the addition of HA will not affect its secondary structure. The addition of HA also promotes the increase in the strength of the intermolecular force and the stability of HA / Fmoc-FRGDF. The higher the HA concentration, the stronger the absorption peak.

[0089] In addition, HA / Fmoc-FRGDF was subjected to an in vitro degradation test, and the results showed that the addition of HA could slow down the degradation rate of HA / Fmoc-FRGDF and improve the stability of the hydrogel, which is of great significance for the sustained release of active substances.

[0090] In addition, the loading capacity and controlled release capacity of HA / Fmoc-FRGDF were tested, with Que as a hydrophobic drug model. The results showed that HA can improve its loading capacity for Que and significantly delay the in vitro release of Que.

[0091] Finally, transmission electron microscopy (TEM) results showed that the Que-loaded HA / Fmoc-FRGDF hydrogel did not destroy the nanofibrous structure of the peptide.

[0092] The embodiments described above are only some embodiments of the present invention, not all embodiments. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention claimed for protection, but only represents selected embodiments of the present invention. All other embodiments obtained without creative work and related deductions and substitutions made by ordinary technicians in the field under the conditions of the present invention are within the scope of protection of the present invention.

Claims

1. Application of hyaluronic acid in improving the performance of polysaccharide-polypeptide composite hydrogels, It is characterized in that In the concentration range of 0.1 to 1.5 mg / mL, HA was used to reduce the mechanical properties of polysaccharide-polypeptide composite hydrogels; In the concentration range of 0.1 to 1.5 mg / mL, hyaluronic acid was used to slow down the degradation rate of polysaccharide-polypeptide composite hydrogel; The polypeptide is Fmoc-FRGDF; The preparation method of the polysaccharide-polypeptide composite hydrogel comprises: dissolving hyaluronic acid and polypeptide in water, adding NaOH solution, HCl solution and PBS buffer, shaking to dissolve and defoam; The ratio of the raw materials for preparation is: 70 μL NaOH solution, 65 μL HCl solution, 465 μL PBS buffer and 10 mg polypeptide per 400 μL water; The concentration of NaOH solution is 0.5M, the concentration of HCl solution is 0.1M, the concentration of PBS buffer is 0.1M, and the pH is 7.4.

Citation Information

Patent Citations

  • Films formed from self-assembling peptide hydrogels

    AU2022327162A1

  • Preparation method and application of injectable hyaluronic acid hydrogel

    CN104140541A

  • Sustained-release topical drug delivery system containing a composition for accelerating autogenous bone recovery and pharmaceutical composition containing the same

    KR102565364B1

  • Malleable hydrogel hybrids made of self-assembled peptides and biocompatible polymers and uses thereof

    US20130079421A1

  • Hydrogel and uses thereof

    WO2023205854A1